@article{da48d7f8a66e4f48804fd75805575fca,
title = "Patterns and predictors of successful treatment discontinuation in retinal vein occlusions with macular edema in the real world",
abstract = "Background And Objective: To identify factors associated with successful treatment discontinuation in eyes with retinal vein occlusions (RVOs) and macular edema (ME) in real-world settings. Patients And Methods: Retrospective study of 214 eyes with RVO and ME with 24-month follow-up at five academic centers. Regression analyses identified factors associated with (1) successful treatment discontinuation for at least 6 months without fluid recurrence and (2) best-corrected visual acuity (BCVA) at 24 months. Results: Forty percent of eyes with branch RVO and 35% with central RVO (CRVO) / hemi-retinal RVO (HRVO) successfully discontinued therapy without fluid recurrence, with median time to discontinuation of 6 and 7 months, respectively. Lower 6-month central subfield thickness was associated with greater likelihood of treatment discontinuation within 24 months for eyes with CRVO/ HRVO (P = .001), whereas better 6-month BCVA was associated with better 24-month BCVA for all RVO subtypes (P < .001). Conclusion: Early anatomic response at 6 months is associated with greater likelihood of stopping treatments.",
author = "Therlinder Lo and Daniella Lent-Schochet and Luu, {Kieu Yen} and Kuriyan, {Ajay E.} and Weiss, {Menachem Y.} and Rachitskaya, {Aleksandra V.} and Singh, {Rishi P.} and Wai, {Karen M.} and Campbell, {J. Peter} and Kishan Gupta and Eric Nudleman and Chen, {Kevin C.} and Glenn Yiu",
note = "Funding Information: Originally submitted August 14, 2020. Revision received December 23, 2020. Accepted for publication January 5, 2021. Presented at the American Academy of Ophthalmology 2017 Meeting, November 11-14, 2017, in New Orleans, Louisiana. Dr. Kuriyan is supported by NIH P30 EY001319. Dr. Campbell is supported by NIH K12 EY27720 and NIH P30 EY10572, Casey Eye Institute departmental funding, and Research to Prevent Blindness (New York, NY). Dr. Nudleman is supported by NEI K08 EY028999. Dr. Yiu is supported by NIH K08 EY026101, NIH R21 EY031108, Macula Society, and BrightFocus Foundation. The sponsors or funding organizations had no role in the design or conduct of this research. Dr. Kuriyan is on the advisory board for Alimera Sciences, Allergan, Bausch + Lomb, and Regeneron; is on the advisory board for and has received grant money from Genentech; is a speaker for Optos and Spark; and has received grant money from Second Sight during the conduct of this study. Dr. Rachitskaya has received personal fees from Alcon, Allergan, Regeneron, Zeiss, Genentech, and Samsara outside the submitted work. Dr. Singh has received personal fees from Regeneron, Genentech, Novar-tis, Bausch + Lomb, Zeiss, and Gyroscope, as well as grants from Apellis, Aerie, and Graybug during the conduct of the study. Dr. Yiu has received personal fees from Allergan, Alimera, Carl Zeiss Meditec, Genetech, Intergalactic Therapeutics, Regeneron, Topcon, and Verily; grants from ARVO Foundation and BrightFocus Foundation; and grants and personal fees from Clearside Biomedical and Iridex outside the submitted work. The remaining authors report no relevant financial disclosures. Dr. Singh did not participate in the editorial review of this manuscript. Ms. Lo and Ms. Lent-Schochet contributed equally to this paper as first authors. The authors would like to thank clinicians from participating academic sites who contributed patients included in their analysis, including Andreas Lauer, MD; Thomas Hwang, MD; Chris Flaxel, MD; Phoebe Lin, MD, PhD; Steven Bailey, MD; Susanna Park, MD, PhD; Lawrence Morse, MD, PhD; Ala Moshiri, MD, PhD; Mina M. Chung, MD; David Diloreto, MD, PhD; David Kleinman, MD, MBA; and Rajeev Ramchandran, MD, MBA, as well as Parisa Emami-Naeini, MD, for providing guidance for statistical analysis. Address correspondence to Glenn Yiu, MD, PhD, UC Davis Eye Center, 4860 Y Street, Suite 2400, Sacramento, CA 95817; email: gyiu@ucdavis.edu. doi: 10.3928/23258160-20210201-05 Publisher Copyright: {\textcopyright} 2020 Ophthalmic Surgery, Lasers & Imaging Retina. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = feb,
doi = "10.3928/23258160-20210201-05",
language = "English (US)",
volume = "52",
pages = "84--92",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "2",
}